163 related articles for article (PubMed ID: 2713508)
1. Response patterns of purified myeloma cells to hematopoietic growth factors.
Anderson KC; Jones RM; Morimoto C; Leavitt P; Barut BA
Blood; 1989 May; 73(7):1915-24. PubMed ID: 2713508
[TBL] [Abstract][Full Text] [Related]
2. Response patterns of hairy cell leukemia to B-cell mitogens and growth factors.
Barut BA; Cochran MK; O'Hara C; Anderson KC
Blood; 1990 Nov; 76(10):2091-7. PubMed ID: 2242429
[TBL] [Abstract][Full Text] [Related]
3. CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
Urashima M; Chauhan D; Uchiyama H; Freeman GJ; Anderson KC
Blood; 1995 Apr; 85(7):1903-12. PubMed ID: 7535594
[TBL] [Abstract][Full Text] [Related]
4. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
5. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
6. The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia.
Kubonishi I; Seto M; Shimamura T; Enzan H; Miyoshi I
Cancer; 1992 Sep; 70(6):1528-35. PubMed ID: 1516003
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
Zhang XG; Bataille R; Widjenes J; Klein B
Cancer; 1992 Mar; 69(6):1373-6. PubMed ID: 1540875
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A; Grande A; Gamberi B; Bonsi L; Fogli M; Amabile M; Cavo M; Ferrari S; Tura S
Br J Haematol; 1994 Dec; 88(4):760-9. PubMed ID: 7529540
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY; Zhang XG; Rodriguez C; Wijdenes J; Gu ZJ; Morel-Fournier B; Harousseau JL; Bataille R; Rossi JF; Klein B
Blood; 1995 May; 85(9):2521-7. PubMed ID: 7727780
[TBL] [Abstract][Full Text] [Related]
10. BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells.
Tanabe O; Kawano M; Tanaka H; Iwato K; Asaoku H; Ishikawa H; Nobuyoshi M; Hirano T; Kishimoto T; Kuramoto A
Am J Hematol; 1989 Aug; 31(4):258-62. PubMed ID: 2787116
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
Taetle R; Dos Santos B; Ohsugi Y; Koishihara Y; Yamada Y; Messner H; Dalton W
J Natl Cancer Inst; 1994 Mar; 86(6):450-5. PubMed ID: 8120920
[TBL] [Abstract][Full Text] [Related]
12. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
Uchiyama H; Barut BA; Mohrbacher AF; Chauhan D; Anderson KC
Blood; 1993 Dec; 82(12):3712-20. PubMed ID: 8260708
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders.
Hata H; Matsuzaki H; Takeya M; Yoshida M; Sonoki T; Nagasaki A; Kuribayashi N; Kawano F; Takatsuki K
Blood; 1995 Sep; 86(5):1939-45. PubMed ID: 7544648
[TBL] [Abstract][Full Text] [Related]
14. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
15. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors.
Sonneveld P; Schoester M; de Leeuw K
Br J Haematol; 1991 Dec; 79(4):589-94. PubMed ID: 1772780
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo.
Murphy WJ; Keller JR; Harrison CL; Young HA; Longo DL
Blood; 1992 Aug; 80(3):670-7. PubMed ID: 1379086
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and functional characterization of normal and malignant terminal B (plasma) cells.
Anderson KC; Cochran M; Barut BA
Eur J Haematol Suppl; 1989; 51():19-26. PubMed ID: 2627990
[TBL] [Abstract][Full Text] [Related]
18. Lack of a role of interleukin 11 in the growth of multiple myeloma.
Paul SR; Barut BA; Bennett F; Cochran MA; Anderson KC
Leuk Res; 1992; 16(3):247-52. PubMed ID: 1532843
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
